Compare CCB & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | ABCL |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2018 | 2020 |
| Metric | CCB | ABCL |
|---|---|---|
| Price | $73.43 | $5.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $126.67 | $8.40 |
| AVG Volume (30 Days) | 92.1K | ★ 7.2M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 0.78 | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $96.61 | N/A |
| Revenue Next Year | $22.66 | $21.85 |
| P/E Ratio | $92.29 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $66.50 | $2.75 |
| 52 Week High | $120.05 | $6.79 |
| Indicator | CCB | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 51.77 |
| Support Level | $73.44 | $3.42 |
| Resistance Level | $79.50 | $5.63 |
| Average True Range (ATR) | 1.91 | 0.55 |
| MACD | 0.66 | -0.11 |
| Stochastic Oscillator | 99.11 | 16.10 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.